These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12176468)

  • 41. Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine.
    Armstrong VW; Kaltefleiter M; Luy-Kaltefleiter M; Schütz E; Wieland E; Loss M; Winkler M; Ringe B; Oellerich M
    Transplant Proc; 1995 Feb; 27(1):1201-3. PubMed ID: 7533371
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation.
    Bilbao I; Pou L; Allende E; Lázaro JL; Charco R; Hidalgo E; Margarit C
    Transplant Proc; 2001 May; 33(3):2124-6. PubMed ID: 11377472
    [No Abstract]   [Full Text] [Related]  

  • 43. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
    Woodle ES; So S; Jendrisak MD; Perdrizet GA; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
    [No Abstract]   [Full Text] [Related]  

  • 44. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
    Kokado Y; Takahara S; Kyo M; Ichimaru N; Toki K; Wang JD; Okuyama A
    Transplant Proc; 1999; 31(1-2):1151-4. PubMed ID: 10083515
    [No Abstract]   [Full Text] [Related]  

  • 45. Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation.
    Jonas S; Guckelberger O; Bechstein WO; Berg T; Müller AR; Platz KP; Tullius SG; Settmacher U; Steinmüller T; Hopf U; Neuhaus P
    Transplant Proc; 1998 Aug; 30(5):2179-81. PubMed ID: 9723433
    [No Abstract]   [Full Text] [Related]  

  • 46. Acute rejection after renal transplantation with tacrolimus-based therapy in conditions of normal clinical practice.
    Scolari MP; Citterio F; Baldan N; Rigotti P; Castagneto M; Stefoni S; Segoloni G
    Transplant Proc; 2002 Aug; 34(5):1671-2. PubMed ID: 12176529
    [No Abstract]   [Full Text] [Related]  

  • 47. Long-term results and risk factors of quadruple immunosuppression in renal transplantation.
    Hiesse C; Kriaa F; Eschwege P; Boubenider S; Marchand S; Benoit G; Charpentier B
    Transplant Proc; 1999; 31(1-2):1111-2. PubMed ID: 10083496
    [No Abstract]   [Full Text] [Related]  

  • 48. Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept.
    Carl S; Dörsam J; Mandelbaum A; Staehler G; Wiesel M
    Transplant Proc; 1998 Jun; 30(4):1236-7. PubMed ID: 9636502
    [No Abstract]   [Full Text] [Related]  

  • 49. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
    Platz KP; Tullius SG; Mueller AR; Schumacher G; Nüssler N; Neuhaus R; Bechstein WO; Lobeck H; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
    [No Abstract]   [Full Text] [Related]  

  • 50. Primary immunosuppression with tacrolimus in renal transplantation: a single center experience.
    Kim HC; Park SB; Han SY; Whang EA; Jeon DS; Kim HT; Cho WH; Park CH
    Transplant Proc; 2003 Feb; 35(1):217-8. PubMed ID: 12591370
    [No Abstract]   [Full Text] [Related]  

  • 51. Does initial graft function influence the outcome after liver transplantation?
    Mueller AR; Platz KP; Krause P; Neuhaus R; Lobeck H; Neuhaus P
    Transplant Proc; 1998 Jun; 30(4):1464-5. PubMed ID: 9636594
    [No Abstract]   [Full Text] [Related]  

  • 52. Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation.
    Cai TH; Esterl RM; Nichols L; Cigarroa F; Speeg KV; Halff GA
    Transplant Proc; 1998 Jun; 30(4):1413-4. PubMed ID: 9636572
    [No Abstract]   [Full Text] [Related]  

  • 53. Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation.
    Lohmann R; Langrehr JM; Klupp J; Neumann U; Guckelberger O; Müller AR; Nüssler NC; Jonas S; Lang M; Settmacher U; Bechstein WO; Neuhaus PJ
    Transplant Proc; 1999; 31(1-2):380. PubMed ID: 10083151
    [No Abstract]   [Full Text] [Related]  

  • 54. 36-month follow-up of 75 renal allograft recipients treated with steroids, tacrolimus, and azathioprine or mycophenolate mofetil.
    Mucha K; Foroncewicz B; Paczek L; Pazik J; Lewandowska D; Krawczyk A; Pliszczynski J; Gradowska L; Durlik M; Walaszewski J; Nazarewski S; Szmidt J
    Transplant Proc; 2003 Sep; 35(6):2176-8. PubMed ID: 14529880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic rejection in pediatric liver transplantation.
    Cho JH; Bhatnagar V; Andreani P; Muiesan P; Portmann B; Baker A; Mieli-Vergani G; Gibbs P; Rela M; Heaton ND
    Transplant Proc; 1997; 29(1-2):452-3. PubMed ID: 9123078
    [No Abstract]   [Full Text] [Related]  

  • 56. Complete withdrawal of immunosuppression in living donor liver transplantation.
    Oike F; Yokoi A; Nishimura E; Ogura Y; Fujimoto Y; Kasahara M; Kaihara S; Kiuchi T; Egawa H; Uemoto S; Tanaka K
    Transplant Proc; 2002 Aug; 34(5):1521. PubMed ID: 12176465
    [No Abstract]   [Full Text] [Related]  

  • 57. Non-heart-beating donor kidney transplantation under tacrolimus immunosuppression.
    Toda F; Tanabe K; Tokumoto T; Ishikawa N; Koga S; Ito S; Yagisawa T; Toma H
    Transplant Proc; 2000 Nov; 32(7):1726-9. PubMed ID: 11119909
    [No Abstract]   [Full Text] [Related]  

  • 58. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids.
    Asensio M; Margarit C; Chavez R; Ortega J; Charco R; Iglesias J
    Transplant Proc; 2002 Aug; 34(5):1970-1. PubMed ID: 12176650
    [No Abstract]   [Full Text] [Related]  

  • 59. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients.
    Rabkin JM; Rosen HR; Corless CL; Olyaei AJ
    Transplant Proc; 2002 Aug; 34(5):1557-8. PubMed ID: 12176483
    [No Abstract]   [Full Text] [Related]  

  • 60. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report.
    Jurewicz WA
    Transplant Proc; 1999 Nov; 31(7A):64S-66S. PubMed ID: 10576048
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.